{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:30:13Z","timestamp":1765279813877},"reference-count":81,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T00:00:00Z","timestamp":1371686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0065903","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T22:52:27Z","timestamp":1371768747000},"page":"e65903","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy"],"prefix":"10.1371","volume":"8","author":[{"given":"Adam","family":"Szulkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustav","family":"Nilsonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata M.","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pega","family":"Souri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hjerpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"DA Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2486\/indhealth.39.183","article-title":"Pathology of human malignant mesothelioma\u2013preliminary analysis of 1,517 mesothelioma cases","volume":"39","author":"Y Suzuki","year":"2001","journal-title":"Ind Health"},{"key":"ref3","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"JC Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0169-5002(01)00257-4","article-title":"Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma","volume":"34","author":"GL Ceresoli","year":"2001","journal-title":"Lung Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1432-0436.2000.660404.x","article-title":"Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells","volume":"66","author":"X Sun","year":"2000","journal-title":"Differentiation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.1810","article-title":"Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling","volume":"207","author":"X Sun","year":"2005","journal-title":"J Pathol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"GJ Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"F Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2005.02.022","article-title":"Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells","volume":"232","author":"X Sun","year":"2006","journal-title":"Cancer Lett"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.freeradbiomed.2006.04.031","article-title":"Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress","volume":"41","author":"G Nilsonne","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1756-9966-28-92","article-title":"Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure","volume":"28","author":"G Nilsonne","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1556-0864(15)30366-X","article-title":"The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"P Ellis","year":"2006","journal-title":"J Thorac Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11864-008-0071-3","article-title":"Systemic treatments for mesothelioma: standard and novel","volume":"9","author":"HL Kindler","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"GL Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/JTO.0b013e31818b174d","article-title":"Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study","volume":"3","author":"G Hillerdal","year":"2008","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02820015","article-title":"Symptomatic treatment of brain tumor patients with sodium selenite, oxygen, and other supportive measures","volume":"62","author":"A Pakdaman","year":"1998","journal-title":"Biol Trace Elem Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2003.12.013","article-title":"Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy","volume":"93","author":"K Sieja","year":"2004","journal-title":"Gynecol Oncol"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, <etal>et al<\/etal>.. (2009) Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol.","DOI":"10.1007\/s00280-009-1181-8"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","article-title":"Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma","volume":"61","author":"GJ Gordon","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0006-2952(91)90558-M","article-title":"The mechanism of interaction between cisplatin and selenite","volume":"41","author":"GS Baldew","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"ref22","first-page":"389","article-title":"Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin","volume":"4","author":"E Mechetner","year":"1998","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1681::AID-CNCR39>3.0.CO;2-U","article-title":"Multidrug resistance-associated protein expression in clinical gastric carcinoma","volume":"77","author":"K Endo","year":"1996","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3109\/07357901003735659","article-title":"High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients","volume":"28","author":"S Ren","year":"2010","journal-title":"Cancer Invest"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12032-010-9553-9","article-title":"ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer","volume":"28","author":"C Su","year":"2011","journal-title":"Med Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer","volume":"24","author":"G Bepler","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref27","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"RV Lord","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref28","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"C Shih","year":"1997","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"L Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"PA Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"11400","DOI":"10.1073\/pnas.0902204106","article-title":"Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite","volume":"106","author":"E Olm","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0006-2952(02)00981-4","article-title":"Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase","volume":"63","author":"L Bjorkhem-Bergman","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.leukres.2009.09.020","article-title":"Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status","volume":"34","author":"M Matondo","year":"2010","journal-title":"Leuk Res"},{"key":"ref34","first-page":"6118","article-title":"Serum-dependent growth patterns of two, newly established human mesothelioma cell lines","volume":"49","author":"J Klominek","year":"1989","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ijc.2910510220","article-title":"Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature","volume":"51","author":"D Schmitter","year":"1992","journal-title":"Int J Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00418-004-0701-1","article-title":"Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis","volume":"122","author":"MM Philippeaux","year":"2004","journal-title":"Histochem Cell Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/carcin\/11.4.673","article-title":"Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients","volume":"11","author":"K Pelin-Enlund","year":"1990","journal-title":"Carcinogenesis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.2910190505","article-title":"Characterization of EBV-genome negative \u201cnull\u201d and \u201cT\u201d cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma","volume":"19","author":"U Schneider","year":"1977","journal-title":"Int J Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/excr.2000.4915","article-title":"Differentiation of mesothelioma cells is influenced by the expression of proteoglycans","volume":"258","author":"K Dobra","year":"2000","journal-title":"Exp Cell Res"},{"key":"ref40","unstructured":"US food and drug administration (2003) Doxorubicin Hydrochloride product label Rockville, Maryland: FDA. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/050467s050068lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/050467s050068lbl.pdf<\/ext-link> Accessed: 2013\u201302\u201313."},{"key":"ref41","unstructured":"US food and drug administration (1996) Gemzar product label Rockville, Maryland: FDA. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020509s020033lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020509s020033lbl.pdf<\/ext-link> Accessed: 2013\u201302\u201313."},{"key":"ref42","unstructured":"US food and drug administration (2004) Paraplatin product label Rockville, Maryland: FDA. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/20452scs20001_paraplatin_lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/20452scs20001_paraplatin_lbl.pdf<\/ext-link> Accessed: 2013\u201302\u201313."},{"key":"ref43","unstructured":"US food and drug administration (2008) Velcade product label Rockville, Maryland: FDA. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021602s021015lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021602s021015lbl.pdf<\/ext-link> Accessed: 2013\u201302\u201313."},{"key":"ref44","unstructured":"US food and drug administration (2004) Alimta product label Rockville, Maryland: FDA. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/021462lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/021462lbl.pdf<\/ext-link> Accessed: 2013\u201302\u201313."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","article-title":"Pemetrexed in malignant pleural mesothelioma","volume":"11","author":"M Hazarika","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref46","first-page":"1231","article-title":"Pharmacokinetics of carboplatin after i.v. administration","volume":"71","author":"F Elferink","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"ref47","unstructured":"Team RDC (2012) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing."},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","article-title":"Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma","volume":"48","author":"JK Blayney","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/03602530600959599","article-title":"Integrating metabolomics and transcriptomics for probing SE anticancer mechanisms","volume":"38","author":"TW Fan","year":"2006","journal-title":"Drug Metab Rev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1158\/0008-5472.CAN-05-2216","article-title":"Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells","volume":"66","author":"R Zhao","year":"2006","journal-title":"Cancer Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1742-4658.2008.06800.x","article-title":"Effects of the antioxidant Pycnogenol on cellular redox systems in U1285 human lung carcinoma cells","volume":"276","author":"V Gandin","year":"2009","journal-title":"FEBS J"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1158\/1535-7163.MCT-06-0063","article-title":"Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide\/p53\/Bax-mediated activation of mitochondrial pathway","volume":"5","author":"H Hu","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2003.08.021","article-title":"Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide","volume":"66","author":"TS Kim","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10565-007-9022-1","article-title":"Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells","volume":"24","author":"E Rudolf","year":"2008","journal-title":"Cell Biol Toxicol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bcp.2005.02.023","article-title":"The role of thioredoxin reductase activity in selenium-induced cytotoxicity","volume":"69","author":"Z Madeja","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"ref56","first-page":"197","article-title":"Selenite (75Se) as a tumor-localizing agent in man","volume":"7","author":"RR Cavalieri","year":"1966","journal-title":"J Nucl Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1385\/BTER:106:3:193","article-title":"Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite","volume":"106","author":"T Zimmermann","year":"2005","journal-title":"Biol Trace Elem Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.onc.1209809","article-title":"Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors","volume":"26","author":"AC Borczuk","year":"2007","journal-title":"Oncogene"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1038\/cddis.2011.58","article-title":"The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance","volume":"2","author":"D Barbone","year":"2011","journal-title":"Cell Death Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e52753","DOI":"10.1371\/journal.pone.0052753","article-title":"Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression","volume":"7","author":"D Barbone","year":"2012","journal-title":"PLoS One"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"DA Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"PG Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"PG Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"RZ Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"J Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"ref66","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"J Adams","year":"1999","journal-title":"Cancer Res"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"ES Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"ref68","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"R LeBlanc","year":"2002","journal-title":"Cancer Res"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"RZ Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"A Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-08-3034","article-title":"Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome","volume":"15","author":"W Ma","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1038\/onc.2009.264","article-title":"Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)","volume":"28","author":"A Arlt","year":"2009","journal-title":"Oncogene"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"J Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejphar.2011.04.057","article-title":"Sustained activation of ERK and Cdk2\/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells","volume":"663","author":"TY Yang","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-4598-11-25","article-title":"Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells","volume":"11","author":"A Buque","year":"2012","journal-title":"Mol Cancer"},{"key":"ref76","first-page":"3671","article-title":"Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma","volume":"59","author":"JL Tonkinson","year":"1999","journal-title":"Cancer Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002800050608","article-title":"Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis","volume":"39","author":"JL Tonkinson","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ab.2011.02.030","article-title":"The reduction of water-soluble tetrazolium salt reagent on the plasma membrane of epidermal keratinocytes is oxygen dependent","volume":"414","author":"L Weir","year":"2011","journal-title":"Anal Biochem"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1023\/A:1012292230480","article-title":"The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma","volume":"12","author":"Y Soini","year":"2001","journal-title":"Ann Oncol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"GJ Gordon","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-012-1965-0","article-title":"A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma","volume":"70","author":"ZG Zimling","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0065903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T14:00:32Z","timestamp":1688306432000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0065903"}},"subtitle":[],"editor":[{"given":"David L.","family":"McCormick","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,20]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0065903","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,20]]}}}